Galectin Therapeutics Inc. (GALT)

[biotech2010]

The CX trial is the last chance for GALT to be successful (my analysis)

Here are some of my notes from the conference call:

They have a private investor committed to helping finance the remaining funds needed to complete the study.

The private investor already has a significant position in GALT and committed the new $1.5M with the FX trial data already completed.

They are still in the process of completing results for the FX patients in the Alpha2 Macroglobulin that were significant in the Phase 1 and will release them when they are finished.

They have 4 patients who have completed the full 1 year trial for CX and 67 who have completed 6 months of the trial so there is the chance for interim results to be released sooner than December, 2017

I think GALT screwed the pooch on even starting the FX trial without a clear indication that they could be successful. They had significant data for Alpha2 Macroglobulin but didn't make it a primary endpoint, that really makes no sense to me as a tech-savvy, non-biotech person.

I have my original shares and had added many October options this week that were paid out of short term trading profits last week that will undoubtedly expire worthless. I am holding my original shares but will essentially put my interest in GALT on the backburner until such time as they show me something of merit-if I lose the full investment I have in GALT my life won't change